Suppr超能文献

[卒中后癫痫发作与癫痫]

[Seizures and epilepsies after stroke].

作者信息

Hamer H M

机构信息

Neurologische Universitätsklinik, UKGM Marburg, Marburg, Germany.

出版信息

Nervenarzt. 2009 Apr;80(4):405-14. doi: 10.1007/s00115-009-2680-x.

Abstract

Epilepsies after stroke represent 20% of all adult-onset epilepsies and exhibit special characteristics with respect to diagnosis, treatment, and prognosis. Patients are frequently amnestic for their seizures the signs of which can be very subtle. Postictal pareses and confusional states can last for days, which further complicate diagnosis. Single seizures after stroke were reported in 2% to 10% of cases, and community-based studies found epilepsies in 3% to 4% of stroke patients. Analyses of subgroups identified epilepsy risks of 3% after ischemic infarction, 6% to 10% after intracerebral hemorrhage, and 9% after subarachnoid hemorrhage. Status epilepticus developed in less than 1% of stroke patients. Besides etiology, further risk factors for epilepsy comprise: remote seizures (latency >2 weeks, risk of recurrence >50%) more than early seizures (latency <2 weeks, risk of recurrence <50%), extent of stroke, cortical involvement, and degree of neurological deficit. The first appearance of seizures in patients older than 60 years represents a risk factor for future stroke with a hazard ratio of 2.89.There is currently no sufficient evidence for starting AED treatment before seizures occur. The benefit is still unclear of starting AED after a single early post-stroke seizure. Most authors recommend AED treatment after the second seizure but also after a first remote seizure because of the high risk of seizure recurrence in these situations. Possible pharmacokinetic interactions should be considered when choosing AED. Especially the first-generation AED carry the potential to interact with comedication, which is usually seen in stroke patients receiving substances such warfarin and salicylates. Only very few studies investigate specific AED exclusively in stroke patients. Lamotrigine and gabapentin have been successfully tested in these patients.

摘要

卒中后癫痫占所有成人起病癫痫的20%,在诊断、治疗和预后方面具有特殊特征。患者常常对其发作没有记忆,发作迹象可能非常隐匿。发作后轻瘫和意识模糊状态可持续数天,这使诊断进一步复杂化。卒中后单次发作的报告发生率为2%至10%,基于社区的研究发现3%至4%的卒中患者患有癫痫。亚组分析确定,缺血性梗死患者癫痫风险为3%,脑出血后为6%至10%,蛛网膜下腔出血后为9%。癫痫持续状态在不到1%的卒中患者中发生。除病因外,癫痫的其他危险因素包括:迟发性发作(潜伏期>2周,复发风险>50%)多于早发性发作(潜伏期<2周,复发风险<50%)、卒中范围、皮质受累情况以及神经功能缺损程度。60岁以上患者首次出现癫痫发作是未来发生卒中的危险因素,风险比为2.89。目前没有足够证据支持在癫痫发作前开始抗癫痫药物(AED)治疗。卒中后单次早发性发作后开始使用AED的益处仍不明确。大多数作者建议在第二次发作后以及首次迟发性发作后开始AED治疗,因为在这些情况下癫痫复发风险很高。选择AED时应考虑可能的药代动力学相互作用。尤其是第一代AED有与合并用药相互作用的潜在风险,这在接受华法林和水杨酸盐等药物的卒中患者中常见。只有极少数研究专门针对卒中患者研究特定的AED。拉莫三嗪和加巴喷丁已在这些患者中成功进行了试验。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验